Acronym:
SADAL
ACTRN/NCT /ethics:
KCP-330-009
Scientific title:
Summary of trial and patient characteristics
Cancer Type | Lymphoma | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II | Tumour Stream | Lymphoma |
Age Range | 18 years and older | Cancer Stage | All stages |
Sex | Both | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | Lymphoma |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Molecular Target | |
Tumour Stream | Lymphoma |
Cancer Stage | All stages |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
A Phase 2b open-label study of selinexor in patients with relapsed/ refractory diffuse large B-cell lymphoma. Selinexor against diffuse aggressive lymphoma.
Lay Summary
Sponsor / Cooperative group
KaryoPharm
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Ashford Cancer Centre Research | Sue Yeend | syeend@adelaidecancercentre.com.au | 08 8292 2240 | Recruitment on Hold |